Peter Jirak

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction

Tarek Bekfani, Mohamed M. Bekhite, Steffen Derlien et al. · Circulation Heart Failure · 2020 · 82 citations · Full text

A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure

Michael Lichtenauer, Peter Jirak, Bernhard Wernly et al. · European Journal of Internal Medicine · 2017 · 64 citations

Novel Cardiovascular Biomarkers, Heart Failure, Chronic Heart Failure +8

Effect of the COVID-19 Pandemic on Treatment Delays in Patients with ST-Segment Elevation Myocardial Infarction

Sebastian J. Reinstadler, Martin Reindl, Ivan Lechner et al. · Journal of Clinical Medicine · 2020 · 55 citations · Full text

Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction

Lukas J. Motloch, Aysilu Hamitova, Krioni Ilja et al. · Journal of Clinical Medicine · 2020 · 46 citations · Full text